Search

Displaying results 221 - 230 of 337 in total
  1. Drug

    Tocopherol

    go.drugbank.com/drugs/DB11251
    ApprovedInvestigational

    Tocopherol exists in four different forms designated as α, β, δ, and γ. They present strong antioxidant activities, and it is determined as the major form of vitamin E. Tocopherol, as a group, is composed of soluble phenolic compounds th...

    Mixtures: Anti-Stretch Mark
  2. Drug

    Nusinersen

    go.drugbank.com/drugs/DB13161
    ApprovedInvestigational

    An antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S. FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is ad...

  3. Drug

    Voretigene neparvovec

    go.drugbank.com/drugs/DB13932
    ApprovedInvestigational

    Voretigene Neparvovec-rzyl (VN-rzyl) is an adeno-associated virus vector-based gene therapy. An adeno-associated virus is a small virus that infects humans and other primates. It is not pathogenic and it causes a very mild immune respons...

  4. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

  5. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    [L12216] This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion.

  6. Drug

    Fenobam

    go.drugbank.com/drugs/DB12931
    Investigational

    Fenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance

  7. Drug

    Triplizumab

    go.drugbank.com/drugs/DB30669
    Investigational

    triplizumab is a biologic drug. triplizumab is under investigation in clinical trial NCT06486220 (PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized

  8. Drug

    Pembrolizumab

    go.drugbank.com/drugs/DB09037
    ApprovedInvestigational

    [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1.

  9. Drug

    Fomivirsen

    go.drugbank.com/drugs/DB06759
    ApprovedWithdrawn

    Fomivirsen is a antisense 21 mer phosphorothioate oligonucleotide.

  10. Drug

    Povidone

    go.drugbank.com/drugs/DB11061
    ApprovedInvestigationalWithdrawn

    somewhat controversial, as it was demonstrated in a few clinical studies that the application of the compound in wounds was associated with impaired wound healing, reduced wound strength, or infection in open